Sulindac enhances the killing of cancer cells exposed to oxidative stress.
BACKGROUND:Sulindac is an FDA-approved non-steroidal anti-inflammatory drug (NSAID) that affects prostaglandin production by inhibiting cyclooxygenases (COX) 1 and 2. Sulindac has also been of interest for more than decade as a chemopreventive for adenomatous colorectal polyps and colon cancer. PRIN...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2009-06-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2686156?pdf=render |